GCC Erectile Dysfunction Drugs Market
GCC Erectile Dysfunction Drugs Market Size Set to Grow at CAGR of 9% to Reach USD 115.32 Million by 2029
Published | 04 September 2023
GCC erectile dysfunction drugs market is gaining traction because of the rising prevalence of erectile dysfunction caused by poor lifestyle choices.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the GCC erectile dysfunction drugs market size at USD 68.83 million in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the GCC erectile dysfunction drugs market size to grow at a CAGR of 8.98% reaching a value of USD 115.32 million by 2029. The GCC erectile dysfunction drugs market is expected to grow mainly due to increased erectile dysfunction prevalence brought on by the poor lifestyle choices made by the male population as well as greater knowledge and acceptance of the condition and its treatment.
GCC Erectile Dysfunction Drugs Market – Overview
According to Mayo Clinic, erectile dysfunction (impotence) is the inability to get and keep an erection firm enough for sex. ED can have a variety of reasons and can signal underlying health issues including diabetes, high cholesterol, or other conditions like heart disease. Drugs used to treat ED work by boosting blood flow to the penis, which aids in achieving and maintaining an erection. The most often recommended treatments for ED are sildenafil (Viagra) and tadalafil (Cialis), which also have favorable clinical outcomes.
Sample Request @ https://www.blueweaveconsulting.com/report/gcc-erectile-dysfunction-drugs-market/report-sample
GCC Erectile Dysfunction Drugs Market
Segmental Information
GCC Erectile Dysfunction Drugs Market – By Product
Based on product, the GCC erectile dysfunction drugs market is divided into Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (alprostadil cream), and others. Viagra (sildenafil citrate) holds the highest share of the GCC erectile dysfunction drugs market by product. Viagra boosts blood flow to the penis when sexually stimulated and assists in maintaining an erection by relaxing a few smooth muscles. As a result, pharmaceutical companies are launching generic sildenafil citrate pills in the market to tap into the growing market opportunities, propelling the overall market growth.
Impact of COVID-19 on GCC Erectile Dysfunction Drugs Market
The unprecedented COVID-19 pandemic presented new growth opportunities for the GCC dysfunction drugs market. Several studies revealed that the COVID-19 infection caused a 20% increase in the prevalence of erectile dysfunction among men. According to an article published in the International Journal of Impotence Research, the psychological burden of the COVID-19 infection and direct testicular damage influenced the chances of ED among men during the pandemic. As a result, the demand for erectile dysfunction drugs spiked in the GCC countries during the pandemic, increasing the overall market growth.
Competitive Landscape
Major players operating in the GCC erectile dysfunction drugs market include Pfizer, Eli Lilly and Company, Teva, Sun Pharmaceutical, Lupin Limited, Glenmark Pharmaceuticals Limited, Cipla Ltd, Sanofi, Apricus Biosciences, and Bayer AG.
To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and the GCC Erectile Dysfunction Drugs Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the GCC Erectile Dysfunction Drugs Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
About Us
BlueWeave Consulting provides comprehensive Market Intelligence (MI) Solutions to businesses regarding various products and services online and offline. We offer all-inclusive market research reports by analyzing qualitative and quantitative data to boost the performance of your business solutions. BlueWeave has built its reputation by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.
Contact Us:
BlueWeave Consulting & Research Pvt. Ltd
+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662
Get Help
Related Report
Publish Date: September 2023
Increasing awareness about the drugs for the treatment of erectile dysfunction (ED) and growing prevalence of ED driven by poor lifestyle choices and stress are expected to boost the expansion of GCC Erectile Dysfunction Drugs Market during the forecast period between 2023 and 2029.
Relevant Press Releases
- US Animal Healthcare Market Anticipated Grow at a CAGR of 7.6% during 2022-2028
- Laser Therapy Market is Expected to Reach USD XX Million By 2027
- Saudi Arabia In Vitro Diagnostics (IVD) Market to Cross USD 1,841.2 Million by 2028
- Benign Prostatic Hyperplasia Treatment Market to Surpass USD 17.6 Billion by 2028
- Global Recombinant Cell Culture Supplements Market to Witness a CAGR of 12.5% during Forecast Period